Neuland Laboratories Limited — Q3 FY25 earnings call

Call held 11 Feb 2025

Management summary

Neuland Labs reported a transitional quarter, with flat top-line growth and core margin pressure, consistent with its revised full-year guidance. The quarter's profit was significantly boosted by an exceptional gain. The key highlight was a strategic ₹254 crore investment into peptide capabilities, positioning the company for long-term growth in a high-value segment, though near-term revenue visibility from this is low. While FY25 is a year of consolidation, management expressed clear confidence in a return to growth in FY26, supported by the maturation of its CMS pipeline.

Highlights

  • Q3 FY25 Total Income stood at ₹401.9 crores, a slight increase of 1.8% YoY.

  • Q3 EBITDA (excluding exceptional items) was ₹90.3 crores with a margin of 22.5%, down from ₹122.7 crores in Q3 FY24.

  • Q3 PAT was ₹101.4 crores, which includes a one-time exceptional gain of ₹55.8 crores from the sale of an investment property.

  • 9M FY25 Revenue saw a marginal degrowth of 1.7% to ₹1,161.5 crores.

  • Management reiterated its guidance for FY25 to be a 'relatively flat' year in terms of revenue.

  • Announced a major strategic CAPEX of ₹254 crores for enhancing peptide manufacturing capacity, with a 3-5 year ramp-up period.

  • The company maintains a strong balance sheet with a negative net debt position of ₹185.1 crores.

  • Management is confident that business growth will resume from FY26, driven by the CMS pipeline.

Key financials

4 periods

Headline

  • Net Debt
    ₹-185.1 Cr

Q3

  • Total Income
    ₹401.9 Cr
    YoY +1.8%
  • PAT
    ₹101.4 Cr
    YoY +25.7%
  • Gross Margin
    53.2%

Q3, ex-exceptional

  • EBITDA
    ₹90.3 Cr
    YoY -26.4%
  • EBITDA Margin
    22.5%

9M

  • Revenue
    ₹1,161.5 Cr
    YoY -1.7%

What they filed

Q1 FY27: revenue up 119.1%, net profit up 950.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue311 398 328 293 514 +65%440 +11%776 +137%642 +119%
EBITDA61 86 51 34 155 +154%77 −10%307 +502%223 +556%
Net profit32 101 28 14 96 +200%40 −60%213 +661%147 +950%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Custom Manufacturing Solutions (CMS)
    ₹156 Cr Q3 Revenue

Guidance & targets

Revenue

  • Full Year Revenue Revenue · FY25 · High confidence Relatively flat

    Previously Moderate growth → Relatively flat

    we expect FY25 to close on a relatively flat level, which is in line with the comments we had made last quarter as well.

    — Saharsh Davuluri

  • Business Growth Revenue · FY26 onwards · Medium confidence Resume growth
    Yes, I think as we had said earlier, we expected FY25 to be a kind of a flattish year, and we also had stated previously that we expect growth to resume from FY26 onwards and therefore we expect our business to continue growth from FY26 onwards as well.

    — Saharsh Davuluri

Pipeline

  • New Commercial Molecules (from pre-commercial) Pipeline · FY26 · High confidence At least 1
    One, at least, maybe two, but we will have to wait and see because again these are still going through trials and filings, etc. But one, we are fairly certain will happen in the next year.

    — Saharsh Davuluri

  • Peptide DMF Filings Pipeline · Future · Medium confidence 2 (Tirzepatide, Difelikefalin)
    So, the plan is to file maybe two DMFs for the generics business. One of it would be a GLP-1 tirzepatide and this is public information. We've disclosed it before. And another peptide called difelikefalin.

    — Saharsh Davuluri

Capex

  • Peptide Facility Ramp-up Capex · next 3-5 years · Medium confidence Ramp-up period
    It will probably take 3 to 5 years to ramp up this investment.

    — Saharsh Davuluri

Risks & concerns

  • Inherent business volatility and lumpiness

    medium

    Management repeatedly stressed that quarter-on-quarter results are uneven, making short-term forecasting difficult.

    Management acknowledged

  • Long gestation period for peptide capex

    medium

    The ₹254 crore investment will take 3-5 years to ramp up, with no definitive visibility on revenues or cash flows at present.

    Management acknowledged

  • Guidance revision from 'moderate growth' to 'flat' for FY25

    medium

    Management attributes the revision to dispatch timing rather than underlying product performance issues, but it still represents a slowdown from initial expectations.

    Both downplayed

Areas of evasion (1)

  • Specific CMS product details (e.g., Bempedoic Acid, cardiovascular drug)

Q&A highlights

2 direct, 1 evasive
Specifics on CMS molecule Bempedoic Acid Evasive
Sorry, Ayush. We don't respond to any questions on a specific CMS molecule because of the confidential nature of the business. So, therefore we would not be able to comment on any question that you ask about a specific CMS molecule.

Demonstrates the strict confidentiality around the high-value CMS business, making it difficult for investors to model specific product contributions.

Asked by Ayush Agarwal

Strategic rationale and details of the ₹254 crore peptide capex Direct
these are not product-specific investments. So, to your question, there is not one anchor product or one anchor customer for which this investment is being made. We are looking at it as an opportunistic investment to kind of take us into that peptide domain by giving us a larger piece of infrastructure.

Clarifies that the large capex is a strategic platform investment for future growth in both CMS and GDS, not a risky bet on a single product or client.

Asked by Shyam Srinivasan

Reason for the sharp YoY decline in 9M development revenue Direct
It's only that a molecule which was in say pre-reg phase moved to commercial during the course of the year and I think that moved at the end of Q2, so from Q3 will be recognized as commercial revenue.

Explains that a significant financial shift was due to a positive event (molecule commercialization and revenue reclassification) rather than a slowdown in the development pipeline.

Asked by Sachin Kasera

2 min read 5 chapters

Detailed narrative

Q3 & 9M FY25 Performance: A Year of Consolidation

Neuland Labs reported a flat performance for Q3 FY25, with total income rising just 1.8% YoY to ₹401.9 crores. Core profitability was under pressure, as EBITDA excluding exceptional items fell to ₹90.3 crores from ₹122.7 crores a year ago, with the margin contracting to 22.5% due to business mix and higher operational costs. The 9-month revenue showed a marginal 1.7% degrowth to ₹1,161.5 crores. This performance aligns with management's reiterated guidance for a 'relatively flat' FY25, marking it as a year of transition before the next growth phase.

Strategic Pivot: The ₹254 Crore Bet on Peptides

The most significant announcement was a ₹254 crore CAPEX into peptide manufacturing capabilities. This investment is not tied to a single product but is a strategic platform build-out, encompassing large-scale commercial, pilot, and R&D facilities. Management plans to leverage this for both its generic (GDS) and custom manufacturing (CMS) businesses, with plans to file two generic peptide DMFs, including the high-potential GLP-1 molecule Tirzepatide. However, the company has guided for a 3-5 year ramp-up period, indicating this is a long-term strategic play with no immediate revenue impact.

CMS Dynamics: Commercialization Offsets Development Lull

The Custom Manufacturing Solutions (CMS) segment generated revenues of ₹156 crores in Q3. A key clarification during the call was the nature of the 9M development revenue, which appeared to decline sharply. Management explained this was due to a large molecule successfully transitioning from the pre-registration phase to commercial status at the end of Q2. Consequently, its revenue is now booked under 'commercial', explaining the shift. This indicates pipeline maturation rather than a slowdown in R&D activity.

Outlook: Flat FY25, Confident on FY26 Growth Resumption

Management was clear in setting expectations for the near term, confirming FY25 will be a flat year. This is a downward revision from the 'moderate growth' guided at the start of the year, attributed to shifts in dispatch schedules. However, they expressed strong confidence that growth will resume in FY26. This optimism is underpinned by the existing order pipeline and the expected commercialization of at least one new molecule from the pre-commercial stage in the next fiscal year.

Strong Balance Sheet and Capital Allocation

Despite the flat growth, Neuland's financial health remains robust. The company reported a negative net debt of ₹185.1 crores, indicating a strong cash position. Over the first nine months, it invested ₹147 crores in capital expenditure while generating a free cash flow of ₹70.8 crores. This demonstrates the company's ability to internally fund its significant growth projects, including the new peptide facility, without stressing its balance sheet.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls